The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
In light of the contributions of these three institutes, it was decided to organize a CSIR Startup Conclave in Hyderabad. The event, scheduled for April 22–23, 2025
Findings likely to generate hypotheses about potential new uses of drugs
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Aurigene.AI is an end-to-end solution for small molecule drug discovery
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design
SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Subscribe To Our Newsletter & Stay Updated
